Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QZB
|
|||
| Former ID |
DIB012733
|
|||
| Drug Name |
F-1394
|
|||
| Synonyms |
AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Discontinued in Phase 1 | [1] | |
| Company |
Fujirebio KK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H61N3O6
|
|||
| Canonical SMILES |
CCCCCCCCCN(CC(C)(C)C)C(=O)NC1CCCCC1OC(=O)CCNC(=O)C2C(COC(O2)(C)C)(C)C
|
|||
| InChI |
1S/C33H61N3O6/c1-9-10-11-12-13-14-17-22-36(23-31(2,3)4)30(39)35-25-18-15-16-19-26(25)41-27(37)20-21-34-29(38)28-32(5,6)24-40-33(7,8)42-28/h25-26,28H,9-24H2,1-8H3,(H,34,38)(H,35,39)/t25-,26-,28?/m0/s1
|
|||
| InChIKey |
NWLFOBZKYXKBOF-QIELNMHASA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Liver carboxylesterase (CES1) | Target Info | Modulator | [2] |
| KEGG Pathway | Drug metabolism - other enzymes | |||
| Metabolic pathways | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Heroin metabolism | ||||
| Irinotecan Pathway | ||||
| Fluoropyrimidine Activity | ||||
| Phase I biotransformations, non P450 | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003109) | |||
| REF 2 | ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits. J Lipid Res. 2001 Apr;42(4):480-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.